264 related articles for article (PubMed ID: 37195587)
1. Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.
Iurlo A; Bucelli C; Cattaneo D
Curr Treat Options Oncol; 2023 Jul; 24(7):802-820. PubMed ID: 37195587
[TBL] [Abstract][Full Text] [Related]
2. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan.
Baba T; Hashimoto Y; Yasuda H; Araki M; Edahiro Y; Morishita S; Ochiai T; Shirane S; Ando J; Komatsu N
Hematology; 2022 Dec; 27(1):157-166. PubMed ID: 35068369
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
4. Developments in diagnosis and treatment of essential thrombocythemia.
Mora B; Passamonti F
Expert Rev Hematol; 2019 Mar; 12(3):159-171. PubMed ID: 30793984
[TBL] [Abstract][Full Text] [Related]
5. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
[TBL] [Abstract][Full Text] [Related]
6. Myeloproliferative neoplasms in adolescents and young adults.
Amerikanou R; Lambert J; Alimam S
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101374. PubMed ID: 36333071
[TBL] [Abstract][Full Text] [Related]
7. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract][Full Text] [Related]
8. Management of essential thrombocythemia.
Cervantes F
Hematology Am Soc Hematol Educ Program; 2011; 2011():215-21. PubMed ID: 22160037
[TBL] [Abstract][Full Text] [Related]
9. [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Garcia-Pallarols F; Longarón R; Ancochea À; Besses C
Med Clin (Barc); 2015 Mar; 144(6):247-53. PubMed ID: 25192581
[TBL] [Abstract][Full Text] [Related]
10. Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.
Tosoni L; Liberi M; Morelli G; Zannier ME; Lazzarotto D; Filì C; Simeone E; Battaglia G; Callegari C; Fanin M; Damiani D; Fanin R; Tiribelli M
Ann Hematol; 2024 Feb; 103(2):443-448. PubMed ID: 38072850
[TBL] [Abstract][Full Text] [Related]
11. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
12. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of the revised International Prognostic Score of Thrombosis for essential thrombocythemia (IPSET-thrombosis) in a cohort of 746 Chinese adult patients].
Fu RF; Li HY; Xue F; Liu XF; Liu W; Huang YT; Chen YF; Zhang LY; Zhang L; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):92-96. PubMed ID: 28279030
[No Abstract] [Full Text] [Related]
15. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
16. Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.
Hashimoto Y; Nakamae H; Tanaka T; Omura H; Horiuchi M; Yoshimura T; Takakuwa T; Mugitani A; Hirose A; Nakamae M; Koh H; Hino M
Eur J Haematol; 2018 Oct; 101(4):508-513. PubMed ID: 29971894
[TBL] [Abstract][Full Text] [Related]
17. How I treat essential thrombocythemia.
Beer PA; Erber WN; Campbell PJ; Green AR
Blood; 2011 Feb; 117(5):1472-82. PubMed ID: 21106990
[TBL] [Abstract][Full Text] [Related]
18. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
19. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
20. A clinical update in polycythemia vera and essential thrombocythemia.
Tefferi A; Solberg LA; Silverstein MN
Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]